Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
Mohamed Shanavas(Princess Margaret Cancer Centre), Vikas Gupta(Princess Margaret Cancer Centre), Murat O. Arcasoy(Duke Medical Center), Navneet S. Majhail, Laura C. Michaelis(Medical College of Wisconsin), James Davies(Oxford University Hospitals NHS Trust), Rebecca B. Klisovic(Goethe University Frankfurt), Parameswaran Hari(Medical College of Wisconsin), Brenda Ernst(Mayo Clinic in Arizona), Ahmad Hanif(Medical College of Wisconsin), Richard Champlin(The University of Texas MD Anderson Cancer Center), Eshetu G. Atenafu(University Health Network), John M. Storring(McGill University Health Centre), Rizwan Romee(Harvard University), Uday Popat(The University of Texas MD Anderson Cancer Center), Usama Gergis(Thomas Jefferson University Hospital), John Mascarenhas(Icahn School of Medicine at Mount Sinai), Antonio Pagliuca, Srđan Verstovšek(The University of Texas MD Anderson Cancer Center), Roni Tamari(Memorial Sloan Kettering Cancer Center), Sumithira Vasu(The Ohio State University), Rammurti T. Kamble(Baylor College of Medicine), Oluchi C. Ukaegbu(Vanderbilt University Medical Center), Veena Fauble(Mayo Clinic in Arizona), Donal P. McLornan(University College Hospital)
Cited by 142
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783